Guiding treatment with resistance testing

The most recent guidelines issued by the British HIV Association (BHIVA), the EuroGuidelines Resistance Group, the US Department of Health and Human Services, and the IAS-USA all recommend the routine use of resistance testing in patient care. Genotypic testing is generally preferred in treatment-experienced patients on a first- or second-line regimen because it is widely available and relatively cost-effective. However, phenotypic testing can be more informative in patients with complex resistance patterns. See the Treatment guidelines section for more specifics on recommendations for resistance testing. 

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.